Aarti Pharmalabs
Other · 3 quarters tracked · source-linked performance and management context.
Latest revenue
₹583 Cr
verified financial record
Quarters tracked
3
source records in the directory
Delivery assessment
67
Across 6 tracked commitments: 4 delivered, 2 missed.
Call date
2026-04-??
latest available source date
Signal trajectory
3 actual quartersCurrent read
67/100
Across 6 tracked commitments: 4 delivered, 2 missed.
Latest source read
What changed this quarter?
Aarti Pharmalabs reported Q4 FY26 standalone revenue of ₹580 crore (+9% YoY), but EBITDA fell to ₹134 crore (-5% YoY) and PAT dropped to ₹62 crore (-30% YoY), impacted by a ₹33 crore forex loss and cost inflation from West Asia tensions. The CDMO segment posted record quarterly revenue of ₹155 crore (+32% YoY), while the xanthine derivatives segment also hit a record at ₹227 crore. API/intermediates remained soft due to pricing pressure. Management guided for 15-18% revenue and EBITDA growth over the next 3-4 years, with CDMO expected to grow 40-50% in FY27. Key risks include persistent raw material inflation, inability to fully pass through costs in the API segment, and lumpy CDMO revenue recognition.
Colored figures compare against the previous available record. Hover or focus one for the comparison.
Signal
Watch
Revenue
₹583 Cr
Source date
2026-04-??
Across the record
Quarter history.
History modules